Article
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
The New England journal of medicine - 25 Jan 2018
Zeuzem Stefan, Foster Graham R, Wang Stanley, Asatryan Armen, Gane Edward, Feld Jordan J, Asselah Tarik, Bourlière Marc, Ruane Peter J, Wedemeyer Heiner, Pol Stanislas, Flisiak Robert, Poordad Fred, Chuang Wan-Long, Stedman Catherine A, Flamm Steven, Kwo Paul, Dore Gregory J, Sepulveda-Arzola Gladys, Roberts Stuart K, Soto-Malave Ruth, Kaita Kelly, Puoti Massimo, Vierling John, Tam Edward, Vargas Hugo E, Bruck Rafi, Fuster Francisco, Paik Seung-Woon, Felizarta Franco, Kort Jens, Fu Bo, Liu Ran, Ng Teresa I, Pilot-Matias Tami, Lin Chih-Wei, Trinh Roger, Mensa Federico J
Abstract excerpt
BACKGROUND: Glecaprevir and pibrentasvir are direct-acting antiviral agents with pangenotypic activity and a high barrier to resistance. We evaluated the efficacy and safety of 8-week and 12-week courses of treatment with 300 mg of glecaprevir plus 120 mg of pibrentasvir in patients without cirrhosis who had hepatitis C virus (HCV) genotype 1 or 3 infection. METHODS: We conducted two phase 3, randomized,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.